Every DEF 14A that Aptevo Therapeutics Inc (APVO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow APVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APVO filings page.
Aptevo Therapeutics Inc. (APVO) is calling a virtual special stockholder meeting on September 22, 2026 to vote on four proposals. Proposal 1 would adopt an amended and restated certificate of incorporation that consolidates prior amendments, updates the company’s address, confirms perpetual duration, incorporates the Series A Junior Participating Preferred Stock designation, and makes technical and administrative clarifications.
Proposal 2 seeks stockholder approval under Nasdaq Listing Rule 5635(d) for the potential issuance of 20% or more of existing common shares or voting power through Inducement Warrants and Common Warrants. These include 1,274,610 Inducement Warrants, 861,708 Pre-Funded Warrants, and 4,308,540 Common Warrants, each with a $4.03 exercise or purchase price. The related August 2026 transactions generated approximately $4.5 million in gross proceeds, with up to about $1.0 million of additional proceeds from exercised prior warrants. Without approval, the Inducement and Common Warrants are not exercisable and the company must keep calling meetings every 60 days while the warrants remain outstanding.
Proposal 3 would approve the Fifth Amended and Restated 2018 Stock Incentive Plan, adding 180,000 new shares (plus up to 152,360 remaining under the current plan and certain returning shares), with a new plan term through 2036 and governance features such as no repricing, minimum one-year vesting (with limited exceptions), director award caps, no tax gross-ups, and clawback provisions. Proposal 4 would allow adjournment of the meeting to solicit more proxies if needed. The board recommends voting “FOR” all four proposals.
Aptevo Therapeutics Inc. is asking stockholders to vote at a virtual annual meeting on August 21, 2026 on four key items. Stockholders will elect two directors, Zsolt Harsanyi and Barbara Lopez Kunz, to serve until the 2029 annual meeting, and vote on ratifying Baker Tilly US, LLP as independent auditor for 2026.
Investors will also cast a non-binding advisory "say‑on‑pay" vote on executive compensation for 2025 and consider approving the Fourth Amended and Restated 2018 Stock Incentive Plan, which would add 145,000 shares (market value $633,650 as of July 23, 2026) to the equity pool, on top of 7,360 shares remaining. There were 1,517,945 shares of common stock outstanding as of the July 23, 2026 record date.
The Board reports that 71% of directors are independent and all Audit, Compensation, and Nominating and Corporate Governance committee members are independent. The refreshed stock plan includes features such as no option repricing without stockholder approval, minimum one‑year vesting (with limited exceptions), a $1,000,000 annual cap on non‑employee director compensation, and clawback provisions tied to company policies and applicable law.
Aptevo Therapeutics is asking stockholders to approve three items at a virtual special meeting on February 18, 2026. The first would adopt an amended and restated certificate of incorporation that consolidates prior amendments, updates the company’s address, confirms perpetual duration, clarifies certain Delaware law voting provisions, and formally includes the designation of Series A Junior Participating Preferred Stock. The second seeks approval, under Nasdaq rules, for the potential issuance of 19.99% or more of the company’s common stock outstanding as of January 8, 2026 under a $60.0 million Standby Equity Purchase Agreement with Yorkville, which allows Aptevo to draw capital over 36 months at a discount to market VWAP. The third proposal would allow the meeting to be adjourned to solicit additional proxies if there are not enough votes for Proposals 1 or 2. There were 997,830 shares of common stock outstanding and entitled to vote as of January 9, 2026.